Search research articles
Contact Us
Filters
Showing results (101-110 of 160) with videos related to
Page
of 16
Sort By:
Leukemia & Lymphoma
|
March 8, 2000
Granulocyte-colony stimulating factor (G-CSF)-primed, delayed marrow harvests as a source of hematopoietic stem and progenitor cells for allogeneic transplantation
G L Phillips, D D Davey, G A Hale, et al.
Bone Marrow Transplantation
|
February 1, 1993
Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide
D E Reece, M J Barnett, J M Connors, et al.
Bone Marrow Transplantation
|
January 1, 1995
Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation
D E Reece, J D Shepherd, H G Klingemann, et al.
Bone Marrow Transplantation
|
May 1, 1992
Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation
T J Nevill, M H Tirgan, H J Deeg, et al.
Blood
|
December 15, 1991
Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]
H G Klingemann, A P Grigg, K Wilkie-Boyd, et al.
Seminars in Oncology
|
June 1, 1987
High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update
S N Wolff, R H Herzig, G L Phillips, et al.
Bone Marrow Transplantation
|
October 21, 2000
Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma
D E Reece, D A Brockington, G L Phillips, et al.
Medical and Pediatric Oncology
|
January 1, 1982
Bone marrow transplantation with high-dose cytosine arabinoside
R H Herzig, H M Lazarus, J Graham-Pole, et al.
Bone Marrow Transplantation
|
January 1, 1994
Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies
H G Klingemann, J D Shepherd, D E Reece, et al.
Blood
|
December 3, 1998
A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease
D Przepiorka, G L Phillips, V Ratanatharathorn, et al.
Page
of 16
Search research articles
Search
Showing results (101-110 of 160) with videos related to
Sort By:
Page
of 16
Leukemia & Lymphoma
|
March 8, 2000
Granulocyte-colony stimulating factor (G-CSF)-primed, delayed marrow harvests as a source of hematopoietic stem and progenitor cells for allogeneic transplantation
G L Phillips, D D Davey, G A Hale, et al.
Bone Marrow Transplantation
|
February 1, 1993
Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide
D E Reece, M J Barnett, J M Connors, et al.
Bone Marrow Transplantation
|
January 1, 1995
Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation
D E Reece, J D Shepherd, H G Klingemann, et al.
Bone Marrow Transplantation
|
May 1, 1992
Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation
T J Nevill, M H Tirgan, H J Deeg, et al.
Blood
|
December 15, 1991
Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]
H G Klingemann, A P Grigg, K Wilkie-Boyd, et al.
Seminars in Oncology
|
June 1, 1987
High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update
S N Wolff, R H Herzig, G L Phillips, et al.
Bone Marrow Transplantation
|
October 21, 2000
Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma
D E Reece, D A Brockington, G L Phillips, et al.
Medical and Pediatric Oncology
|
January 1, 1982
Bone marrow transplantation with high-dose cytosine arabinoside
R H Herzig, H M Lazarus, J Graham-Pole, et al.
Bone Marrow Transplantation
|
January 1, 1994
Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies
H G Klingemann, J D Shepherd, D E Reece, et al.
Blood
|
December 3, 1998
A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease
D Przepiorka, G L Phillips, V Ratanatharathorn, et al.
Page
of 16